First Allied Advisory Services’s Agios Pharmaceuticals AGIO Stock Holding History

First Allied Advisory Services’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,785	Closed	-$233K	–	1181
2018 Q2	$233K	Sell	2,785 -9,310	-77%	-$812K	0.01%	986
2018 Q1	$985K	Buy	+12,095	New	+$935K	0.04%	454
2015 Q1	–	Sell	-2,250	Closed	-$251K	–	1075
2014 Q4	$251K	Buy	+2,250	New	+$201K	0.02%	838

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

First Allied Advisory Services's AGIO Position: Q3 2018 in Review

First Allied Advisory Services sold out of Agios Pharmaceuticals (AGIO) in Q3 2018, closing a stake of 2,785 shares — an estimated $233K sold.

First Allied Advisory Services first reported a position in AGIO in Q4 2014 and held it in 3 quarters. The position peaked at $985K in Q1 2018. 208 funds tracked by Wall St. Rank hold AGIO as of Q3 2018.

First Allied Advisory Services reported no remaining Agios Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
First Allied Advisory Services sold 2,785 Agios Pharmaceuticals shares in Q3 2018, an estimated $233K.
First Allied Advisory Services first reported a position in Agios Pharmaceuticals in Q4 2014 and held it in 3 quarters.
First Allied Advisory Services's Agios Pharmaceuticals position peaked at $985K in Q1 2018.
208 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2018.

Based on First Allied Advisory Services's 13F filing for Q3 2018, filed 14 Nov 2018.